ValoreQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25Q1, 26Q2, 26TTMSpese di vendita, generali e amministrative53.14 M56.18 M63.67 M63.37 M63.76 M69.74 M76.08 M272.95 MRicerca e sviluppo21.14 M21.31 M23.92 M18.05 M17.01 M17.13 M19.7 M71.89 MReddito operativo-36.04 M-34.64 M-41.56 M-30.12 M-29.93 M-32.9 M-45.86 M-138.82 MProventi non operativi, Totale1.32 M3.17 M2.55 M1.85 M2.91 M2.65 M1.89 M9.29 MOneri finanziari, al netto degli interessi capitalizzati29 K24 K143 K—————Proventi non operativi, esclusi gli oneri finanziari3.59 M3.22 M2.66 M2.69 M2.49 M2.17 M1.71 M9.06 MEntrate/uscite straordinarie-2.3 M-69 K-251 K-836 K420 K471 K175 K230 KUtile al lordo delle imposte-34.75 M-31.5 M-39.15 M20.58 M-26.88 M-30.25 M-43.98 M-80.53 MQuota di utile————————Imposte-96 K97 K175 K191 K256 K253 K43 K743 KInteressi di minoranza————————Altri proventi/oneri al netto delle imposte—20 K-831 K-1.15 M-240 K336 K498 K-558 KUtile netto al lordo delle attività cessate-34.66 M-31.59 M-39.33 M20.39 M-27.14 M-30.51 M-44.02 M-81.28 MAttività cessate————————Utile netto-34.66 M-31.59 M-39.33 M20.39 M-27.14 M-30.51 M-44.02 M-81.28 MRegolazione della diluizione————————Dividendi privilegiati————————Utile netto diluito attribuibile agli azionisti ordinari-34.66 M-31.59 M-39.33 M20.39 M-27.14 M-30.51 M-44.02 M-81.28 MUtile base per azione (EPS base)-0.59-0.53-0.660.34-0.45-0.5-0.71-1.32Utile diluito per azione (EPS diluito)-0.59-0.53-0.660.33-0.44-0.5-0.71-1.32Numero medio di azioni ordinarie in circolazione58.02 M59.16 M59.65 M59.99 M59.81 M61.08 M61.7 M—Azioni diluite in circolazione58.02 M59.16 M59.65 M61.16 M59.81 M61.08 M61.7 M—EBITDA-29.39 M-28.26 M-35.16 M-24.05 M-23.93 M-26.71 M-39.45 M-114.14 MEBIT-36.04 M-34.64 M-41.56 M-30.12 M-29.93 M-32.9 M-45.86 M-138.82 MCosto del fatturato46.48 M45.87 M46.77 M44.76 M48.17 M49.73 M53.59 M196.25 MAltri costi del venduto————————Ammortamento e svalutazione (liquidità)6.66 M6.38 M6.4 M6.07 M6 M6.19 M6.41 M24.68 M
Twist Bioscience Corporation - Common Stock
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
The company was represented by Leproust at a March 2021 tabletop exercise at the Munich Security Conference simulating an outbreak of weaponized monkeypox.
In May 2021, Twist Bioscience and Genome Project-Write launched a new CAD platform for whole genome design. The CAD will automate workflows to enable collaborative efforts critical for scale-up from designing plasmids to megabases across entire genomes.